ABBOTT LABORATORIES (ABL.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:ABL - US0028241000 - Common Stock
111.06 EUR
+0.36 (+0.33%)
ABL gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 63 industry peers in the Health Care Equipment & Supplies industry. ABL scores excellent points on both the profitability and health parts. This is a solid base for a good stock. ABL has a decent growth rate and is not valued too expensively. With these ratings, ABL could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
ABL had positive earnings in the past year.
In the past year ABL had a positive cash flow from operations.
In the past 5 years ABL has always been profitable.
Each year in the past 5 years ABL had a positive operating cash flow.
1.2 Ratios
ABL's Return On Assets of 16.60% is amongst the best of the industry. ABL outperforms 93.65% of its industry peers.
ABL has a better Return On Equity (27.43%) than 95.24% of its industry peers.
The Return On Invested Capital of ABL (9.90%) is better than 82.54% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ABL is in line with the industry average of 9.33%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.6% | ||
| ROE | 27.43% | ||
| ROIC | 9.9% |
ROA(3y)11.2%
ROA(5y)9.84%
ROE(3y)20.61%
ROE(5y)19.06%
ROIC(3y)10.45%
ROIC(5y)10.18%
1.3 Margins
ABL's Profit Margin of 31.88% is amongst the best of the industry. ABL outperforms 100.00% of its industry peers.
ABL's Profit Margin has improved in the last couple of years.
The Operating Margin of ABL (18.29%) is better than 77.78% of its industry peers.
ABL's Operating Margin has improved in the last couple of years.
ABL has a Gross Margin (56.19%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of ABL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.29% | ||
| PM (TTM) | 31.88% | ||
| GM | 56.19% |
OM growth 3Y-5.79%
OM growth 5Y2.63%
PM growth 3Y24.85%
PM growth 5Y22.55%
GM growth 3Y-0.89%
GM growth 5Y-1.07%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ABL is creating some value.
Compared to 1 year ago, ABL has about the same amount of shares outstanding.
Compared to 5 years ago, ABL has less shares outstanding
The debt/assets ratio for ABL has been reduced compared to a year ago.
2.2 Solvency
ABL has an Altman-Z score of 5.84. This indicates that ABL is financially healthy and has little risk of bankruptcy at the moment.
ABL's Altman-Z score of 5.84 is amongst the best of the industry. ABL outperforms 90.48% of its industry peers.
ABL has a debt to FCF ratio of 1.87. This is a very positive value and a sign of high solvency as it would only need 1.87 years to pay back of all of its debts.
ABL has a better Debt to FCF ratio (1.87) than 82.54% of its industry peers.
A Debt/Equity ratio of 0.23 indicates that ABL is not too dependend on debt financing.
ABL has a better Debt to Equity ratio (0.23) than 69.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | 1.87 | ||
| Altman-Z | 5.84 |
ROIC/WACC1.19
WACC8.29%
2.3 Liquidity
A Current Ratio of 1.70 indicates that ABL should not have too much problems paying its short term obligations.
ABL's Current ratio of 1.70 is in line compared to the rest of the industry. ABL outperforms 52.38% of its industry peers.
A Quick Ratio of 1.24 indicates that ABL should not have too much problems paying its short term obligations.
ABL has a Quick ratio (1.24) which is comparable to the rest of the industry.
The current and quick ratio evaluation for ABL is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.7 | ||
| Quick Ratio | 1.24 |
3. Growth
3.1 Past
ABL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.40%, which is quite good.
The Earnings Per Share has been growing slightly by 7.59% on average over the past years.
Looking at the last year, ABL shows a small growth in Revenue. The Revenue has grown by 6.37% in the last year.
ABL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.63% yearly.
EPS 1Y (TTM)10.4%
EPS 3Y-3.58%
EPS 5Y7.59%
EPS Q2Q%7.44%
Revenue 1Y (TTM)6.37%
Revenue growth 3Y-0.88%
Revenue growth 5Y5.63%
Sales Q2Q%6.9%
3.2 Future
The Earnings Per Share is expected to grow by 10.09% on average over the next years. This is quite good.
ABL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.12% yearly.
EPS Next Y11.45%
EPS Next 2Y10.79%
EPS Next 3Y10.83%
EPS Next 5Y10.09%
Revenue Next Year6.43%
Revenue Next 2Y7.06%
Revenue Next 3Y7.17%
Revenue Next 5Y7.12%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ABL is valuated quite expensively with a Price/Earnings ratio of 25.77.
ABL's Price/Earnings ratio is a bit cheaper when compared to the industry. ABL is cheaper than 71.43% of the companies in the same industry.
When comparing the Price/Earnings ratio of ABL to the average of the S&P500 Index (26.15), we can say ABL is valued inline with the index average.
The Price/Forward Earnings ratio is 22.43, which indicates a rather expensive current valuation of ABL.
ABL's Price/Forward Earnings ratio is in line with the industry average.
The average S&P500 Price/Forward Earnings ratio is at 36.12. ABL is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.77 | ||
| Fwd PE | 22.43 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as ABL.
Based on the Price/Free Cash Flow ratio, ABL is valued a bit cheaper than 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 32.35 | ||
| EV/EBITDA | 20.51 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of ABL may justify a higher PE ratio.
PEG (NY)2.25
PEG (5Y)3.4
EPS Next 2Y10.79%
EPS Next 3Y10.83%
5. Dividend
5.1 Amount
ABL has a Yearly Dividend Yield of 1.90%. Purely for dividend investing, there may be better candidates out there.
ABL's Dividend Yield is a higher than the industry average which is at 2.22.
ABL's Dividend Yield is slightly below the S&P500 average, which is at 2.41.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.9% |
5.2 History
The dividend of ABL is nicely growing with an annual growth rate of 11.40%!
Dividend Growth(5Y)11.4%
Div Incr Years6
Div Non Decr Years6
5.3 Sustainability
ABL pays out 28.93% of its income as dividend. This is a sustainable payout ratio.
ABL's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP28.93%
EPS Next 2Y10.79%
EPS Next 3Y10.83%
FRA:ABL (11/26/2025, 7:00:00 PM)
111.06
+0.36 (+0.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners80.68%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap193.30B
Revenue(TTM)43.84B
Net Income(TTM)13.98B
Analysts78.89
Price Target125.57 (13.07%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.9% |
Yearly Dividend1.92
Dividend Growth(5Y)11.4%
DP28.93%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-0.82%
Min EPS beat(2)-1.06%
Max EPS beat(2)-0.58%
EPS beat(4)1
Avg EPS beat(4)-0.52%
Min EPS beat(4)-1.16%
Max EPS beat(4)0.73%
EPS beat(8)3
Avg EPS beat(8)0.07%
EPS beat(12)7
Avg EPS beat(12)1.63%
EPS beat(16)11
Avg EPS beat(16)5.69%
Revenue beat(2)0
Avg Revenue beat(2)-0.81%
Min Revenue beat(2)-1.29%
Max Revenue beat(2)-0.33%
Revenue beat(4)0
Avg Revenue beat(4)-1.08%
Min Revenue beat(4)-1.37%
Max Revenue beat(4)-0.33%
Revenue beat(8)0
Avg Revenue beat(8)-0.75%
Revenue beat(12)4
Avg Revenue beat(12)0.15%
Revenue beat(16)8
Avg Revenue beat(16)1.85%
PT rev (1m)1.71%
PT rev (3m)1.57%
EPS NQ rev (1m)-0.02%
EPS NQ rev (3m)0.48%
EPS NY rev (1m)0%
EPS NY rev (3m)0.15%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)0.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.77 | ||
| Fwd PE | 22.43 | ||
| P/S | 5.1 | ||
| P/FCF | 32.35 | ||
| P/OCF | 24.54 | ||
| P/B | 4.39 | ||
| P/tB | 10.46 | ||
| EV/EBITDA | 20.51 |
EPS(TTM)4.31
EY3.88%
EPS(NY)4.95
Fwd EY4.46%
FCF(TTM)3.43
FCFY3.09%
OCF(TTM)4.53
OCFY4.08%
SpS21.76
BVpS25.29
TBVpS10.61
PEG (NY)2.25
PEG (5Y)3.4
Graham Number49.52
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.6% | ||
| ROE | 27.43% | ||
| ROCE | 11.52% | ||
| ROIC | 9.9% | ||
| ROICexc | 11.13% | ||
| ROICexgc | 21.33% | ||
| OM | 18.29% | ||
| PM (TTM) | 31.88% | ||
| GM | 56.19% | ||
| FCFM | 15.78% |
ROA(3y)11.2%
ROA(5y)9.84%
ROE(3y)20.61%
ROE(5y)19.06%
ROIC(3y)10.45%
ROIC(5y)10.18%
ROICexc(3y)12.18%
ROICexc(5y)11.89%
ROICexgc(3y)32.65%
ROICexgc(5y)35.03%
ROCE(3y)12.16%
ROCE(5y)11.86%
ROICexgc growth 3Y-24.08%
ROICexgc growth 5Y-8.19%
ROICexc growth 3Y-10.71%
ROICexc growth 5Y6.04%
OM growth 3Y-5.79%
OM growth 5Y2.63%
PM growth 3Y24.85%
PM growth 5Y22.55%
GM growth 3Y-0.89%
GM growth 5Y-1.07%
F-Score7
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | 1.87 | ||
| Debt/EBITDA | 1.04 | ||
| Cap/Depr | 70.33% | ||
| Cap/Sales | 5.02% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 81.77% | ||
| Profit Quality | 49.49% | ||
| Current Ratio | 1.7 | ||
| Quick Ratio | 1.24 | ||
| Altman-Z | 5.84 |
F-Score7
WACC8.29%
ROIC/WACC1.19
Cap/Depr(3y)63.63%
Cap/Depr(5y)61.92%
Cap/Sales(3y)4.94%
Cap/Sales(5y)5.1%
Profit Quality(3y)82.78%
Profit Quality(5y)99.6%
High Growth Momentum
Growth
EPS 1Y (TTM)10.4%
EPS 3Y-3.58%
EPS 5Y7.59%
EPS Q2Q%7.44%
EPS Next Y11.45%
EPS Next 2Y10.79%
EPS Next 3Y10.83%
EPS Next 5Y10.09%
Revenue 1Y (TTM)6.37%
Revenue growth 3Y-0.88%
Revenue growth 5Y5.63%
Sales Q2Q%6.9%
Revenue Next Year6.43%
Revenue Next 2Y7.06%
Revenue Next 3Y7.17%
Revenue Next 5Y7.12%
EBIT growth 1Y15.18%
EBIT growth 3Y-6.62%
EBIT growth 5Y8.41%
EBIT Next Year27.77%
EBIT Next 3Y15.64%
EBIT Next 5Y12.85%
FCF growth 1Y53.98%
FCF growth 3Y-9.78%
FCF growth 5Y7.14%
OCF growth 1Y39.24%
OCF growth 3Y-6.69%
OCF growth 5Y6.88%
ABBOTT LABORATORIES / ABL.DE FAQ
What is the fundamental rating for ABL stock?
ChartMill assigns a fundamental rating of 7 / 10 to ABL.DE.
What is the valuation status for ABL stock?
ChartMill assigns a valuation rating of 4 / 10 to ABBOTT LABORATORIES (ABL.DE). This can be considered as Fairly Valued.
What is the profitability of ABL stock?
ABBOTT LABORATORIES (ABL.DE) has a profitability rating of 8 / 10.
What are the PE and PB ratios of ABBOTT LABORATORIES (ABL.DE) stock?
The Price/Earnings (PE) ratio for ABBOTT LABORATORIES (ABL.DE) is 25.77 and the Price/Book (PB) ratio is 4.39.
Can you provide the financial health for ABL stock?
The financial health rating of ABBOTT LABORATORIES (ABL.DE) is 8 / 10.